EN
EN
CN
JP
KR
HOME
MOUSE MODELS
MOUSE MODELS
Knockout & Conditional Knockout Mouse Models
Disease Mouse Models
Germ-Free Mouse Models
Tool Mice (Cre-Dre-Flpo-Cas9-Reporter)
Immunodeficient Mouse Models
The Wild Mouse Project
SERVICES
SERVICES
Custom Model Generation Services
Preclinical Testing Services
Germ-Free and Microbiome Services
Cell Lines and Customization Services
Custom Breeding Services
Animal Quality Testing Services
Other Services
NEWS & RESOURCES
NEWS & RESOURCES
News
Events
Webinars
Resources
Promotion
ABOUT US
ABOUT US
GemPharmatech USA
GemPharmatech Headquarters
Facilities
Careers
Contact Us
Quality Management System
Advanced Search
Hot Search:
NCG
Wild Mice
CD3
BAFF
FAD
NCG-X
NCG-hIL15
Research Field:
Immune System
Developmental Biology
Nervous System
Oncolgoy Research
Tool Mice
Humanized Mouse Model
Disease and Drug Evaluation Model
Other Models
Research Field:
Gene humanization model
Tissue humanization model
Humanized flora model
NOD/ShiLtJGpt-Prkdc
em26Cd52
Il2rg
em26Cd22
/Gpt
NCG|Strain NO.T001475
Knockout (KO)
Product Type:
Live Mouse
Sperm
Frozen Embryo
Quantity:
-
+
Sex:
Male
Female
Age:
1 weeks
2 weeks
3 weeks
4 weeks
5 weeks
6 weeks
7 weeks
8 weeks
9 weeks
10 weeks
11 weeks
12 weeks
13 weeks
14 weeks
15 weeks
16 weeks
17 weeks
18 weeks
19 weeks
20 weeks
21 weeks
22 weeks
23 weeks
24 weeks
25 weeks
26 weeks
27 weeks
28 weeks
29 weeks
30 weeks
>30 weeks
Genotype:
(Prkdc)KO/KO,(Il2rg)ko/Y
(Prkdc)KO/KO,(Il2rg)KO/KO
Add to cart
BASIC INFORMATION
Strain Name:
NOD/ShiLtJGpt-Prkdc
em26Cd52
Il2rg
em26Cd22
/Gpt
Strain Number:
T001475
Official Symbol:
Prkdc,Il2rg
Strain Strategy:
T001475.NCG strain info.pdf
Official Full Name:
protein kinase DNA activated catalytic polypeptide,interleukin 2 receptor gamma chain
Also Known As:
AI326420,AU019811,DNA-PKcs,DNAPDcs,DNAPK,DNPK1,DOXNPH,HYRC1,XRCC7,dxnph,p460
NCBI Number:
19090
16186
MGI Number:
104779
96551
Research Areas:
Humanized model,Humanization of the immune system,Immunodeficiency
Strain Background:
[N000235] NOD/ShiLtJGpt
Modification Type:
Knockout (KO)
Inventory Status:
Live,Cryopreserved
Sale Status:
IF (Available for Distribution)
Health Status:
Specific pathogen free (SPF)
Health Report:
Please log in to view
Publications:
1. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment
2. Cytoplasmic NEAT1 Suppresses AML Stem Cell Self‐Renewal and Leukemogenesis through Inactivation of Wnt Signaling
3. Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML
4. Biomimetic Nanoerythrosome‐Coated Aptamer‐DNA Tetrahedron/Maytansine Conjugates: pH‐Responsive and Targeted Cytotoxicity for HER2‐positive Breast Cancer
5. Interferon-a potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment
6. Autologous transplantation of thecal stem cells restores ovarian function in nonhuman primates
7. ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3
8. Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1
9. Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling
10. Creatine promotes cancer metastasis through activation of Smad2/3
11. Rapamycin pretreatment rescues the bone marrow AML cell elimination capacity of CAR-T cells
12. AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia
13. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors
14. Development of an antibody-like T-cell engager based on VH-VL heterodimer formation and its application in cancer therapy
15. The Rational Development of CD5-targeting Biepitopic Chimeric Antigen Receptors with Fully Human Heavy-chain-only Antigen Recognition Domains
16. N7-Methylguanosine tRNA modification enhances oncogenic mRNA translation and promotes intrahepatic cholangiocarcinoma progression
17. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors
18. ARID1A hypermethylation disrupts transcriptional homeostasis to promote squamous cell carcinoma progression
19. ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer stemness
20. Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy
21. Dendrimer-Functionalized Superparamagnetic Nanobeacons for Real-Time Detection and Depletion of HSP90α mRNA and MR Imaging
22. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study
23. OXTR(High) stroma fibroblasts control the invasion pattern of oral squamous cell carcinoma via ERK5 signaling
24. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
25. Acquired semi-squamatization during chemotherapy suggests differentiation as a therapeutic strategy for bladder cancer
26. Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma
27. Identification of novel HLA-A*11:01-restricted HPV16 E6/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy
28. Targeting ARF1-IQGAP1 interaction to suppress colorectal cancer metastasis and vemurafenib resistance
29. Hook&Loop multivalent interactions based on disk-shaped nanoparticles strengthen active targeting
30. Downregulation of phosphoserine phosphatase potentiates tumor immune environments to enhance immune checkpoint blockade therapy
31. BPA‐Containing Polydopamine Nanoparticles for Boron Neutron Capture Therapy in a U87 Glioma Orthotopic Model
32. Anti-BCMA surface engineered biomimetic photothermal nanomissile enhances multiple myeloma cell apoptosis and overcomes the disturbance of NF-kappaB signaling in vivo
33. EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1
34. Expansion of human megakaryocyte-biased hematopoietic stem cells by biomimetic Microniche
35. Supramolecular nanofibers co-loaded with dabrafenib and doxorubicin for targeted and synergistic therapy of differentiated thyroid carcinoma
36. PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
37. Impaired histone inheritance promotes tumor progression
38. NOTCH4(DeltaL12_16) sensitizes lung adenocarcinomas to EGFR-TKIs through transcriptional down-regulation of HES1
39. Targeting Trop2 by Bruceine D suppresses breast cancer metastasis by blocking Trop2/beta-catenin positive feedback loop
40. GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer
41. Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRbeta complex in hepatocellular carcinoma
42. Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment
43. Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models
44. Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma
45. Targeting Bcl-xL is a potential therapeutic strategy for extranodal NK/T cell lymphoma
46. Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin
47. WDR54 exerts oncogenic roles in T-cell acute lymphoblastic leukemia
48. Activation of melanocortin-1 receptor signaling in melanoma cells impairs T cell infiltration to dampen antitumor immunity
49. Downregulation of RCN1 promotes pyroptosis in acute myeloid leukemia cells
50. The application of HER2 and CD47 CAR-macrophage in ovarian cancer
51. A drug-delivery depot for epigenetic modulation and enhanced cancer immunotherapy
52. A human mucosal melanoma organoid platform for modeling tumor heterogeneity and exploring immunotherapy combination options
53. Intratumoral CD103(+) CD8(+) T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma
54. Novel mesothelin-targeted chimeric antigen receptor-modified UNKT cells are highly effective in inhibiting tumor progression
55. The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancer
56. Enhancement of the viability of T cells electroporated with DNA via osmotic dampening of the DNA-sensing cGAS-STING pathway
57. Lipid accumulation-mediated histone hypoacetylation drives persistent NK cell dysfunction in anti-tumor immunity
0
Cart
Contact Us
Strain Manage